Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatm...
Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifo...
“We are very pleased with the continued progress being made in our Hansoh Pharma collaboration,” said Craig Tooman, President and CEO of Silenc...
The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for sale in the UK, pr...
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical ...
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeuti...
The company is pleased to disclose its advancement of up to 12 g or more / L expression of recombinant protein - fully folded / biologically active in ferm...
Funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™ Funding round led by Mercia C...
Under the programme initiated 9 May 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.8 billion in the period from 10 May 2023 to 8 Aug...
Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation A...
Gadoquatrane is a highly stable contrast agent for magnetic resonance imaging (MRI) with high relaxivity and the potential of a substantially lower gadol...
Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage with global regulatory authorities to discuss nex...
By using this cutting-edge imaging technology in preclinical studies, Oncodesign Services’ team hopes to gain insights of the predictive effectivenes...
New data demonstrates the ability of TLX250-CDx to detect extrarenal lesions, supporting potential clinical utility in the metastatic or recurrent setting,...
© 2025 Biopharma Boardroom. All Rights Reserved.
